Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH postmarket reengineering team

This article was originally published in The Gray Sheet

Executive Summary

Thirteen-member group is conducting weekly meetings to collect feedback on postmarket surveillance and discuss potential initiatives. Brian Harvey, CDRH Office of Device Evaluation, co-heads the team with Tom Gross from the Office of Surveillance and Biometrics. After presenting project ideas to outgoing center Director Bruce Burlington Feb. 19, the team will split into subgroups to design pilot programs in areas such as MDR reporting, device tracking, surveillance and Sentinel reporting. The pilots should be in place by early summer

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel